1. Introduction
Multiple acyl-CoA dehydrogenase deficiency (MADD), known as glutaric aciduria type-II, is an autosomal recessive disorder and a cause of lipid storage myopathy (LSM).1 MADD is classified into type-I (neonatal onset with congenital anomalies), type-II (neonatal onset without congenital anomalies), and type-III (late-onset), with type-III being the most common presentation of MADD.2 Neonatal onset types have a poor prognosis with severe metabolic decompensation, including profound hypoglycemia, hyperammonemia, and metabolic acidosis. Late-onset MADD is a milder form commonly afflicted with progressive proximal myopathy, myalgia, and exercise intolerance, though metabolic decompensation may develop.
With late-onset MADD, symptoms can occur from infancy until adulthood. However, the mean age of diagnosis is 17.6 years (ranging from 0.13 yr to 69 yrs). 85.3% of patients present with chronic musculoskeletal symptoms (proximal myopathy, exercise intolerance, muscle pain) and about 33.1% had acute metabolic decompensation (emesis, nonketotic hypoglycemia, metabolic acidosis, or liver dysfunction).3 These presentations were likely precipitated by metabolic stressors such as infection. Low frequency of cardiac arrhythmias, diastolic dysfunction, and rarely sensory neuropathy has been observed.4
2. Case Report
2.1. Case
A 28-year-old male presented to the emergency department with acute on chronic progression of proximal muscle weakness, fatigue, and mild dysphagia. Reviewing the time course of his symptoms, he first began experiencing generalized fatigue approximately 7 months ago. 3 months ago, he began experiencing weakness of the jaw muscles, which made it difficult to chew solid foods, and bilateral thigh weakness. The muscle weakness progressed to involve both his upper and lower extremities, making basic daily tasks difficult. He resorted to using a cane to ambulate and spent most of his days lying down due to this weakness. He continued to experience progression of the muscle weakness in the weeks prior to his current presentation, and this progression in weakness was accompanied by diffuse myalgias, dysphonia, and unintentional weight loss. Past medical history was significant for an episode of rhabdomyolysis in the setting of cyclic vomiting syndrome and vitamin D deficiency. Family history was notable for systemic lupus erythematosus in the mother and rheumatoid arthritis in the paternal grandmother. During this admission, he grew significantly weaker to the extent of becoming bed-bound within 11 days of his initial presentation to the emergency room. The dysphagia progressed to the point of limiting dietary intake, and his respiratory status worsened. He eventually required tracheostomy and gastrostomy tube placement for support. Afterwards, the patient was transferred to the ICU due to the need for a higher level of care (Table 1).
2.2. Differential Diagnosis
When considering the differential diagnoses, other conditions that can share a similar presentation include inflammatory myopathies, mitochondrial myopathies, myasthenia gravis, muscular dystrophy, immune-mediated myopathies, and other inborn disorders of metabolism (including other fatty acid oxidation disorders). Time course of symptoms (onset, duration, and exacerbating factors) are important in distinguishing between these different conditions. In this case, our team obtained additional testing to help further elucidate if any were contributing to the patient’s presentation.
2.3. Investigations
Neurology, rheumatology, endocrinology, and medical genetics (via telehealth) were consulted to aid in diagnosis. HIV ½ Ab, hepatitis B serology, tuberculosis antigen and QuantiFERON, syphilis, and Lyme disease tests returned negative. The patient’s urine protein was 10.3 mg/dL, urine creatinine was 54 mg/dL, complement 3 level was 171 mg/dL, and complement 4 level was 27 mg/dL. An extractable nuclear antigen panel returned negative, as did ANA antibody levels and Anti-DsDNA antibody, and aldolase level was 7.7 units/L, suggesting the etiology was not autoimmune in nature, thus ruling out conditions like dermatomyositis and polymyositis. The anti-HMGCR antibody level was also within normal limits, making immune-mediated necrotizing myopathy less likely in this patient. Acetylcholine receptor antibody levels returned <0.03 nmol/L which helped to rule out myasthenia gravis. Lab workup found multiple abnormalities, including mildly elevated liver function tests, erythrocyte sedimentation rate 11 mm/hr, and C-reactive protein 3.4 mg/dL. Beta-hydroxybutyrate was 3.65 mmol/L, suggesting ketosis. Many metabolites were normal; ammonia returned at 45 umol/dL, and the homocysteine level was 13.7 umol/L. Serum zinc was also normal at 122 mcg/dL, vitamin A 12.4 mcg/dL, vitamin D < 7 ng/mL, alpha tocopherol 7.6mg/dL, and gamma tocopherol 1.5 mg/dL. Tissue transglutaminase antibodies were within normal limits. These findings suggested no absorption abnormalities. An amino acid profile was obtained, which showed elevated hydroxyproline, threonine, asparagine, sarcosine, proline, alpha-aminobutyrate, isoleucine, leucine, and phenylalanine. However, citrulline and cystine were both low. In addition, an acylcarnitine profile revealed high levels of many acylcarnitine species. Urine organic acid analysis was significant for elevated pyruvate, 3-hydroxybutyrate, ethylmalonate, and 4-hydroxyphenyllactate as well as medium-chain dicarboxylic aciduria. These findings were suggestive of a fatty acid
oxidation disorder. Muscle biopsies of the right quadriceps and right deltoid were obtained and showed extensive myofiber necrosis associated with abundant lipid globules. Preliminary genetic testing was sent. Whole exome sequencing revealed ETFDH c. 1084G > A (p. Gly362Arg) Heterozygous, not paternally inherited and likely pathogenic variant; ETFDH c1213A > G (p. Lys405Glu) Heterozygous, paternally inherited variant of uncertain significance; XDH c.1450 C > T (p.Gln484*) Heterozygous, paternally inherited likely pathogenic; Chr3:193,272,496-194,346,762 deletion (1.07 Mb) Heterozygous, not paternally inherited, likely pathogenic. This helped to establish the diagnosis of Glutaric Acidemia Type II/Multiple Acyl-CoA Dehydrogenase Deficiency (Table 2).
2.4. Treatment
He was started on oral coenzyme Q10 (200 mg qAM and 100 mg qPM), riboflavin (250 mg BID), and IV levocarnitine (8 grams TID) as well as a multivitamin, thiamine, vitamin D3, vitamin B12, and triglyceride oil to treat MADD. His hospital course was complicated by a pulmonary embolism that required thrombectomy by interventional radiology and anticoagulation with apixaban. He was transitioned to oral levocarnitine 330 mg TID, and riboflavin was reduced to 300 mg daily, and he remained on all supplements at the time of discharge. The patient was counseled by a nutritionist regarding the importance of following a low-fat, controlled-protein, high-carbohydrate diet. He was eventually transferred to inpatient rehabilitation after initiation of therapy and was able to return to near baseline functional status near the time of his discharge from rehab.
3. Discussion
The initial clinical presentation of MADD can vary from patient to patient, which can make the determination of the diagnosis more difficult. In a retrospective study by Lupica et. al, of all patients who were diagnosed with vacuolar myopathy, fatigue and muscle weakness were the predominant symptoms that were seen at the onset of their presentation.5 Our patient presented with a several-month history of generalized weakness, exercise intolerance, and weight loss, which on initial work-up did not indicate a specific etiology. The patient had gradually made adjustments to his daily activities, was unable to continue with his line of work, and required the use of a cane to ambulate outside of the home. With regards to the onset of dysphagia, typically bulbar involvement, manifesting as dysphagia or dysphonia, in late-onset MADD is uncommon. According to a study by Nilipour et. al,6 only about 10.9% of study patients had bulbar involvement and there was not an observed difference in the frequency of this presentation between men and women. Although a sign of significant clinical deterioration, especially in an acute setting, it has not been established if signs of bulbar weakness, such as dysphagia, are consistent predictors of disease severity in MADD. Adult-onset lipid storage myopathies typically present with more muscle involvement, while childhood presentations can present with a more severe presentation involving the brain and liver.6 As described in the case presentation, clinical suspicion for possible in-born errors of metabolism is often needed in order to guide the treatment team towards a diagnosis in patients who present with lipid storage myopathies.
Guidelines regarding formal criteria for the diagnosis of MADD have not been established in the literature; however, there are several findings that are suggestive of the diagnosis that are more often utilized in patient cases. Confirmatory testing to establish the diagnosis for MADD is done via identification of variants in ETFA, ETFB, or ETFDH genes and by assessment of acylcarnitine levels in blood and/or urine samples .7
Imaging or biopsy of the affected muscle groups in the setting of progressive weakness can give clues to the treatment team that point towards a metabolic cause. With MRI, there may be evidence of edema or infiltration, and if biopsy is pursued can show accumulation of extramitochondrial lipids, which suggests lipid storage myopathy. It is important to note that biopsy and imaging are not needed to make the diagnosis of MADD.7 However, this could be helpful in excluding other causes of myositis or weakness in older patients. For example, in one case report by Zheng et al,8 an 80-year-old woman presented with a 3-month history of progressive weakness and exercise intolerance without evidence of muscle pain and was initially thought to be suffering from myositis. On muscle biopsy, it was shown that the patient had cytoplasmic vacuoles containing lipids, which pointed towards the diagnosis of MADD8.8 Our case summarizes the importance of considering metabolic myopathies and obtaining a thorough patient history when approaching a clinical scenario of a patient who presents with progressive neuromuscular weakness.
Ethics Approval
Written informed consent was obtained from the patient for the publication of this case report.
Availability of Data and Material
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Competing Interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors
Authors’ Contributions
All authors contributed substantially to this report.
Acknowledgements
None.
